Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE:002773)
China · Delayed Price · Currency is CNY 24.49
-0.81 (-3.20%)
Apr 28, 2026, 3:04 PM CST
SHE:002773 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 4,431 | 4,583 | 4,451 | 3,957 | 3,388 | 3,605 |
Other Revenue | 1.88 | 1.88 | 1.49 | 0.63 | 0.64 | 0.19 |
| 4,433 | 4,585 | 4,453 | 3,957 | 3,389 | 3,605 | |
Revenue Growth (YoY) | -2.76% | 2.97% | 12.51% | 16.77% | -6.00% | 9.40% |
Cost of Revenue | 460.83 | 467.39 | 469.43 | 438.84 | 391.66 | 355.66 |
Gross Profit | 3,972 | 4,118 | 3,983 | 3,519 | 2,997 | 3,250 |
Selling, General & Admin | 2,221 | 2,274 | 2,117 | 1,943 | 1,710 | 1,786 |
Research & Development | 525.56 | 533.09 | 579.71 | 421.68 | 374 | 1,008 |
Other Operating Expenses | 72.84 | 52.96 | 53.43 | 52.75 | 48.47 | 51.08 |
Operating Expenses | 2,820 | 2,860 | 2,751 | 2,418 | 2,133 | 2,843 |
Operating Income | 1,152 | 1,257 | 1,232 | 1,101 | 864.46 | 407 |
Interest & Investment Income | 86.7 | 89.58 | 110.18 | 97.53 | 83.14 | 61.55 |
Currency Exchange Gain (Loss) | -0.18 | -0.18 | -0.16 | 0.16 | 0.34 | 0.12 |
Other Non Operating Income (Expenses) | 1.3 | -0.46 | 0.81 | -1.39 | -0.65 | -0.94 |
EBT Excluding Unusual Items | 1,240 | 1,346 | 1,343 | 1,197 | 947.29 | 467.73 |
Impairment of Goodwill | - | - | - | - | - | -214.84 |
Gain (Loss) on Sale of Investments | 1.63 | 0.55 | -1.06 | -0.83 | - | - |
Gain (Loss) on Sale of Assets | -0.05 | 0.01 | 0.01 | 0.01 | - | - |
Asset Writedown | -6.73 | -6.19 | -1.14 | -0.52 | -0.24 | -0.67 |
Other Unusual Items | 17.39 | 15.41 | 11.5 | 38.26 | 83.25 | 141.19 |
Pretax Income | 1,252 | 1,356 | 1,353 | 1,234 | 1,030 | 393.42 |
Income Tax Expense | 199.74 | 210.61 | 175.53 | 202.79 | 164.49 | -27.66 |
Earnings From Continuing Operations | 1,052 | 1,146 | 1,177 | 1,031 | 865.81 | 421.08 |
Minority Interest in Earnings | 18.35 | 17.46 | 14.22 | 13.64 | 30.86 | 0 |
Net Income | 1,070 | 1,163 | 1,191 | 1,045 | 896.67 | 421.08 |
Net Income to Common | 1,070 | 1,163 | 1,191 | 1,045 | 896.67 | 421.08 |
Net Income Growth | -12.10% | -2.37% | 14.02% | 16.52% | 112.94% | - |
Shares Outstanding (Basic) | 923 | 923 | 916 | 916 | 915 | 915 |
Shares Outstanding (Diluted) | 923 | 923 | 916 | 916 | 915 | 915 |
Shares Change (YoY) | 0.24% | 0.73% | -0.01% | 0.16% | -0.05% | 5.16% |
EPS (Basic) | 1.16 | 1.26 | 1.30 | 1.14 | 0.98 | 0.46 |
EPS (Diluted) | 1.16 | 1.26 | 1.30 | 1.14 | 0.98 | 0.46 |
EPS Growth | -12.31% | -3.08% | 14.04% | 16.33% | 113.04% | - |
Free Cash Flow | 1,130 | 1,241 | 1,252 | 1,080 | 569.95 | -75.3 |
Free Cash Flow Per Share | 1.22 | 1.34 | 1.37 | 1.18 | 0.62 | -0.08 |
Dividend Per Share | 0.700 | 0.700 | 0.600 | 0.380 | 0.150 | 0.100 |
Dividend Growth | 16.67% | 16.67% | 57.89% | 153.33% | 50.00% | - |
Gross Margin | 89.60% | 89.81% | 89.46% | 88.91% | 88.44% | 90.14% |
Operating Margin | 25.98% | 27.42% | 27.68% | 27.81% | 25.51% | 11.29% |
Profit Margin | 24.15% | 25.36% | 26.75% | 26.40% | 26.46% | 11.68% |
Free Cash Flow Margin | 25.49% | 27.07% | 28.13% | 27.28% | 16.82% | -2.09% |
EBITDA | 1,390 | 1,494 | 1,462 | 1,322 | 1,021 | 554.33 |
EBITDA Margin | 31.36% | 32.58% | 32.82% | 33.40% | 30.11% | 15.38% |
D&A For EBITDA | 238.18 | 236.37 | 229.14 | 221 | 156.12 | 147.33 |
EBIT | 1,152 | 1,257 | 1,232 | 1,101 | 864.46 | 407 |
EBIT Margin | 25.98% | 27.42% | 27.68% | 27.81% | 25.51% | 11.29% |
Effective Tax Rate | 15.96% | 15.53% | 12.98% | 16.43% | 15.96% | - |
Revenue as Reported | 4,433 | 4,585 | 4,453 | 3,957 | 3,389 | 3,605 |
Advertising Expenses | - | 27.69 | 20.87 | - | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.